This landmark study demonstrated that adding trastuzumab to chemotherapy significantly improved survival and response rates in metastatic HER2-positive breast cancer, while simultaneously highlighting increased cardiotoxicity risks, particularly when combined with anthracyclines. The gene discussed is ERBB2; the disease is breast carcinoma.